Impact of Concomitant Hormone Therapy on the Diagnostic Performance of <sup>18</sup>F‐Piflufolastat PET/CT in Prostate Cancer Patients: A Sub‐Group Analysis of OSPREY Cohort B
The diagnostic performance of <sup>18</sup>F-piflufolastat PET/CT was unaffected by concomitant HT in OSPREY cohort B patients with recurrent and/or metastatic prostate cancer.
Authors
- Nancy Stambler (ORCID: https://orcid.org/0000-0001-9748-0722)
- Michael J. Morris (ORCID: https://orcid.org/0000-0002-9454-0096)
- Vincent A. DiPippo (ORCID: https://orcid.org/0000-0002-5529-4195)
- Saradha Baskaran (ORCID: https://orcid.org/0000-0002-4499-8680)
- Lawrence Saperstein
- Barry A. Siegel (ORCID: https://orcid.org/0000-0001-6246-5792)
- Steven P. Rowe (ORCID: https://orcid.org/0000-0003-2897-4694)
- Michael A. Gorin (ORCID: https://orcid.org/0000-0002-8315-6603)
- Béla Dénes (ORCID: https://orcid.org/0000-0002-9889-529X)
- Kenneth J. Pienta (ORCID: https://orcid.org/0000-0002-4138-2186)
Institutions
- University of North Carolina at Chapel Hill (US)
- Memorial Sloan Kettering Cancer Center (US)
- Johns Hopkins University (US)
- Yale University (US)
- Mallinckrodt (United States) (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The Prostate
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1002/pros.24909
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00